,B.1.351,VOC,Beta,South Africa/,D80A,""" Transmissibility ( 50%)"
0,B.1.351.2,,,December 2020,D215G,
1,B.1.351.3,,,,241del,# Susceptibility to EUA monoclonal
2,,,,,242del,antibody treatments
3,,,,,243del,
4,,,,,K417N,# Neutralization to convalescent &
5,,,,,E484K,post-vaccination sera
6,,,,,N501Y,
7,,,,,D614G,
8,,,,,A701V,
9,P.1,VOC,Gamma,Brazil/,L18F,# Susceptibility to bamlanivimab/
10,P.1.1,,,January 2021,T20N,etesevimab monoclonal antibody
11,P.1.2,,,,P26S,treatments
12,,,,,D138Y,
13,,,,,R190S,# Neutralization to convalescent &
14,,,,,K417T,post-vaccination sera
15,,,,,E484K,
16,,,,,N501Y,
17,,,,,D614G,
18,,,,,H655Y,
19,,,,,T1027I,
20,B.1.617.2,VOI,Delta,India/,T19R,""" Transmissibility"
